Abstract:BACKGROUND:Hepatitis B virus (HBV) infection is the primary cause of hepatitis with chronic HBV infection, which may develop into liver fibrosis, cirrhosis and hepatocellular carcinoma. Detection of early-stage fibrosis related to HBV infection is of great clinical significance to block the progression of liver lesion. Direct liver biopsy is regarded as the gold standard to detect and assess fibrosis; however, this method is invasive and prone to clinical sampling error. In order to address these issues, we attempted to find more convenient and effective serum markers for detecting HBV-induced early-stage liver fibrosis.AIM:To investigate serum N-glycan profiling related to HBV-induced liver fibrosis and verify multiparameter diagnostic models related to serum N-glycan changes.METHODS:N-glycan profiles from the sera of 432 HBV-infected patients with liver fibrosis were analyzed. Significant changed N-glycan levels (peaks) (P < 0.05) in different fibrosis stages were selected in the modeling group, and multiparameter diagnostic models were established based on changed N-glycan levels by logistic regression analysis. The receiver operating characteristic (ROC) curve analysis was performed to evaluate diagnostic efficacy of N-glycans models. These models were then compared with the aspartate aminotransferase to platelet ratio index (APRI) , fibrosis index based on the four factors (FIB-4), glutamyltranspeptidase platelet albumin index (S index), GlycoCirrho-test, and GlycoFibro-test. Furthermore, we combined multiparameter diagnostic models with alanine aminotransferase (ALT) and platelet (PLT) tests and compared their diagnostic power. In addition, the diagnostic accuracy of N-glycan models was also verified in the validation group of patients.RESULTS:Multiparameter diagnostic models constructed based on N-glycan peak 1, 3, 4 and 8 could distinguish between different stages of liver fibrosis. The area under ROC curves (AUROCs) of Model A and Model B were 0.890 and 0.752, respectively differentiating fibrosis F0-F1 from F2-F4, and F0-F2 from F3-F4, and surpassing other serum panels. However, AUROC (0.747) in Model C used for the diagnosis of F4 from F0-F3 was lower than AUROC (0.795) in FIB-4. In combination with ALT and PLT, the multiparameter models showed better diagnostic power (AUROC = 0.912, 0.829, 0.885, respectively) when compared with other models. In the validation group, the AUROCs of the three combined models (0.929, 0.858, and 0.867, respectively) were still satisfactory. We also applied the combined models to distinguish adjacent fibrosis stages of 432 patients (F0-F1/F2/F3/F4), and the AUROCs were 0.917, 0.720 and 0.785.CONCLUSION:Multiparameter models based on serum N-glycans are effective supplementary markers to distinguish between adjacent fibrosis stages of patients caused by HBV, especially in combination with ALT and PLT.

Application of Serum N -Glycan Profiling Diagnostic Model in Evaluation of Liver Fibrosis in Patients with Hepatitis C

Serum N-glycan Markers for Diagnosing Liver Fibrosis Induced by Hepatitis B Virus

Serum N-Glycan Markers for Diagnosing Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels

N-Glycan Based Models Improve Diagnostic Efficacies in Hepatitis B Virus-Related Hepatocellular Carcinoma

Altered serum<i>N</i>-glycomics in chronic hepatitis B patients

Altered Serum N-Glycomics In Chronic Hepatitis B Patients

Serum N-glycomic Markers in Combination with Panels Improves the Diagnosis of Chronic Hepatitis B.

Serum N-glycan Profiling As a Diagnostic Biomarker for the Identification of Hepatitis B Virus-Associated Hepatocellular Carcinoma

Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study

Serological Diagnosis Of Liver Fibrosis By Quantitative Estimation Of Serum Biomarkers Using Luminex Xmap Assay

Evaluation of Noninvasive Diagnostic Models of Liver Fibrosis in Patients with Chronic Hepatitis B

Dynamic Changes of Key Metabolites During Liver Fibrosis in Rats.

A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus.

A novel model based on serum N‐glycan markers for evaluating stage of liver necroinflammation in treatment‐naïve chronic hepatitis B patients

Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B.

Serum Metabolite Profiles Are Associated with the Presence of Advanced Liver Fibrosis in Chinese Patients with Chronic Hepatitis B Viral Infection

Diagnostic Value of Noninvasive Diagnostic Model of Liver Fibrosis in Combination with Serum Hyaluronic Acid in Patients with Chronic Hepatitis B

The Prediction and Validation of Liver Fibrosis by a Noninvasive Model and Validation in Patients with Chronic Hepatitis B

Dose–response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B

Prediction of Significant Fibrosis in HBeAg-positive Patients with Chronic Hepatitis B by a Noninvasive Model

Establishment and Evaluation of a Novel and Non-Invasive Diagnostic Model on Cirrhotic Patients